BRAVEHEART- A new versatile technological Bioartificial drug- eluting caRdiac pAtch to preVEnt HEART failure: from clinically-oriented de-risking activity to the industrial prototyping and preclinical validation
Duration: From 25 Nov 2024 – 24 Nov 2026 (2 years)
Funding Institution: Investimento 2.1 “Valorizzazione e potenziamento della ricerca biomedica del SSN”, Sub-investimento 2.1.1 della Missione 6, Componente 2 del Piano Nazionale di Ripresa e Resilienza finanziato dall’Unione Europea, NextGenerationEU – Project PNRR-POC-2023-12378186
Principal Investigator: Michele Pilato (ISMETT- Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione IRCCS)
Contact person in IPCF: C. Cristallini
Other research units (contact person): University of Turin (Mauro Rinaldi); AOU San Giovanni di Dio e Ruggi d’Aragona (Carmine Vecchione)
ERC Sectors:LS7_4 Regenerative medicine; PE5_7 Biomaterials synthesis; LS7_3 Nanomedicine
Keywords: Cardiac repair; Regeneration; Drug-eluting; Acellular patch
The project represents an integrated clinical-translational effort for the technology transfer of innovative microstructured electro-conductive drug-eluting cardiac patches as revolutionary therapeutic solutions to prevent heart failure. The team involving clinical, academic and research units with complementary expertise (medicine, cardiac surgery, stem cell biology and bioengineering) will conduct the project. The IPCF will lead the production and chemical-physical, mechanical and functional characterization of the developed cardiac patches.
Other IPCF people involved in the research activities: F. Aiello, C. Trouki, D. Rossino